National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Atezolizumab (Tecentriq®) in combination with bevacizumab. HTA ID: 20060

Atezolizumab in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have not received prior systemic therapy.

 

NCPE Assessment Process Complete
Rapid review commissioned 21/12/2020
Rapid review completed 08/02/2021
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of atezolizumab in combination with bevacizumab compared with the current standard of care.